Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olitigaltin - Galecto Inc

Next Previous
Search
Drug Profile

Olitigaltin - Galecto Inc

Alternative Names: GB0-139; TD-139

Latest Information Update: 18 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University; University of Edinburgh
  • Developer Galecto Inc; University of Edinburgh
  • Class Antifibrotics; Antivirals; Small molecules; Thioglycosides
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Idiopathic pulmonary fibrosis

Most Recent Events

  • 15 Aug 2023 Efficacy and adverse events data from a phase IIb trial in Idiopathic pulmonary fibrosis released by Galecto Inc
  • 19 May 2023 Updated pharmacodynamics data from the phase IIb GALACTIC-1 trial in Idiopathic pulmonary fibrosis presented at the 119th International Conference of the American Thoracic Society (ATS-2023 (3804483)
  • 17 May 2023 Galecto completes a phase II GALACTIC-1 trial in Idiopathic pulmonary fibrosis in USA, Australia, Belgium, Canada, France, Georgia, Germany, Ireland, Israel, Italy, Poland, Spain, Ukraine and the UK (Inhalation) (NCT03832946)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top